◆ 会议时间：2026年3月26-28日
◆ 会议地点：日本 横滨
◆ 会议简介：
2026年第23届日本肿瘤内科学会(JSMO)年会将于2026年3月26-28日在日本横滨举行，上次会议有6,800多余名代表参加。
日本肿瘤内科学会/日本臨床腫瘍学会(JSMO)的使命是通过改善癌症的治疗，为社会公益事业做出贡献。为了实现这一目标，JSMO每年召开会议和教育项目，支持癌症研究，探索、研究和传播与癌症患者、家庭成员和癌症研究人员的癌症治疗有关的国内和国际信息；宣促进和鼓励改进癌症医疗技术；制定癌症治疗指南，并从事各种业务活动，以保持与相关组织的联系和合作。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.
第23回日本臨床腫瘍学会学術集会
23rd Annual Meeting of the Japanese Society of Medical Oncology (JSMO)
会期/Date:
2026年3月26日（木）～28日（土）
会場/Venue:
パシフィコ横浜
テーマ/Theme:
Medical Oncologists for Cancer Patients
演題募集期間:
2025年6月12日（木）正午～9月17日（水）正午 → 10月1日（水）正午
Noon, Thursday, June 12, 2025 – Noon, Wednesday, September 17, 2025 (JST) → Noon, Wednesday, October 1, 2025 (JST)
点此提交摘要>>>Submit Abstract>>>
Welcome Greeting
We are pleased to announce that the 23rd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2026) will be held over three days from Thursday, March 26, to Saturday, March 28, 2026, at PACIFICO Yokohama North and Exhibition Hall D (Yokohama, Japan). The theme of this meeting is “Medical Oncologists for Cancer Patients”.
Since 2006, JSMO has been conducting board certification in medical oncology. In 2026, the program will mark its 20th anniversary, having training around 2,000 medical oncologists in Japan. This significant occasion provides an opportunity to explore the ideal role of the “Medical Oncologist”. We will examine their contributions to cancer treatment and research, their role in standardizing cancer care, and their involvement in team-based approaches. Additionally, we aim to consider cancer patients’ perspectives, the required number of specialists, regional and institutional disparities, and issues related to domestic and international board certification systems. Through these discussions, we hope to clarify the future direction of board certification in medical oncology.
JSMO2026 will also focus on "Asian Oncology," highlighting contributions from Asia regarding clinical oncology for cancer treatment. We aim to revisit the history of outstanding basic research and novel evidence on anti-cancer drug development originating from Asian countries, including Japan, across various cancer fields. Furthermore, we will explore the future of collaborative research in Asia, and address opportunities for oncologic education as well as the relationships among young oncologists in the region.
In addition, JSMO2026 will showcase the latest high-level evidence in oncology, fostering in-depth discussions during the meeting. We look forward to receiving numerous general abstract submissions on these subjects from both domestic and international participants. Through active discussions on the latest evidence, we aim to further promote international collaboration and advancements in the field.
The meeting will also cover various topics, such as anti-cancer drug development, cancer genome medicine, personalized medicine, perioperative chemotherapy, and cancer care tailored to different life stages (including pediatrics, the AYA generation, and elderly cancer patients). Additional topics include onco-fertility, hereditary tumors, and the intersection of cancer care with patients, their families, and society.
Late March in Japan is typically a season of pleasant weather, with cherry blossoms in full bloom. We hope that many colleagues from both Japan and overseas will join us, enriching academic discussions and enjoying the scenic views and culinary delights of the port city of Yokohama.
We look forward to welcoming you and sharing this meaningful occasion together.
Sincerely,
The 23rd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2026)
Congress President
Vice-president of JSMO
Chair, Board Certification Committee
Kenji Tamura, M.D., Ph.D
(Professor, Department of Medical Oncology, Shimane University Hospital)
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
